Indonesia University

ui.ac.id

Total trials

440

Active

49

Phase 3

38

Total enrollment

58,257

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Esomeprazole2
Propolis drops1
Vonoprazan 20 mg1
Simvastatin 40mg2
Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) Therapy1
Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) Therapy1
uc-msc secretome intra cavernous1
Triple combination cream1
Oral Vitamin C1
injection of local anesthesia solution1
Injection of normal saline1
Concentrated secretome Injection 3 mL1
Concentrated secretome Injection 3 mL with addition of TGF Beta 31

Next readouts

  • 2025-03
  • 2025-04-25
  • 2025-05
  • 2025-05-26
  • 2025-06-30
  • 2025-12-31
  • 2025-12-31
  • 2026-04-01
  • 2026-05-14

Top conditions

  • Obesity10
  • Sepsis7
  • Surgery7
  • Quality of Life6
  • Oxidative Stress6
  • Acne Vulgaris6
  • Anesthesia6
  • Diabetes Mellitus6

Frequently asked questions about Indonesia University

How many clinical trials does Indonesia University have on ClinicalTrials.gov?
Indonesia University is listed as the lead sponsor on 440 clinical trials in ClinicalTrials.gov, 49 of which are currently active (recruiting, enrolling, or ongoing).
How many of Indonesia University's trials are in Phase 3?
38 of Indonesia University's trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does Indonesia University focus on?
Indonesia University's most-studied conditions on ClinicalTrials.gov are Obesity, Sepsis, Surgery, Quality of Life, Oxidative Stress.
When are Indonesia University's next clinical trial readouts?
Indonesia University has 9 upcoming primary-completion readouts tracked here; the soonest is “Effect of Vitamin C Supplementation in Corneal Endothelial Damage in Phacoemulsification of Patients with Hard Cataracts”, expected around 2025-03.